Corbus Pharmaceuticals Holdings Inc.
Rank 26
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
$7.34
USD
-1.28%
Market cap
$473,101,322
Total volume
$7,332,793
Shares outstanding
64,455,221
Rank 26
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
Markets
| Exchange | Symbol | Volume (24h) | Volume (%) | Price |
|---|---|---|---|---|
|
|
CRBP |
$7,332,793
|
100% |
$7.34
|
Chart